Clinical trial · Interventional
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
NCT04349267CI-TRIAL-00099101completedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- BMS-986315
- interventionNames
- Biological: BMS-986315
- type
- EXPERIMENTAL
- label
- BMS-986315 + nivolumab
- interventionNames
- Biological: BMS-986315
- Biological: nivolumab
- type
- EXPERIMENTAL
- label
- BMS-986315 + cetuximab
- interventionNames
- Biological: BMS-986315
- Biological: cetuximab
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1 * Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor * Eastern cooperative oncology group performance status of 0 or 1 * Women of childbearing potential must agree to follow methods of contraception Exclusion Criteria: * Participants with active, known or suspected autoimmune disease * Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications * Uncontrolled or significant cardiovascular disease * History of or with active interstitial lung disease or pulmonary fibrosis * Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study * History of allergy or hypersensitivity to study drug components Other protocol-defined inclusion/exclusion criteria apply
References
Publications (0)
Data not yet available
No reference posted for this study.